Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brightline-1 brigimadlin versus doxorubicin in advanced dedifferentiated liposarcoma
NL-OMON59058Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Liposarcoma comparing Brigimadlin with Doxorubicin (2 arms). Primary endpoint: Progression-free survival. Started Jun 2022; status: completed.
02
Drugs
brigimadlindoxorubicin
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on NL-OMON59058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59058.